Want to see ATAI full AI Analyst Report?
ATAI Stock Chart & Stats
$7.39
>-$0.01(-0.14%)
At close: 4:00 PM EDT
$7.39
>-$0.01(-0.14%)
Day’s Range― - ―
52-Week Range$3.27 - $7.45
Previous CloseN/A
Volume9.63M
Average Volume (3M)8.34M
Market Cap
$2.72B
Enterprise Value$1.68K
Total Cash (Recent Filing)$225.81M
Total Debt (Recent Filing)$4.29M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Nov 12, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.90
Shares Outstanding370,864,650
10 Day Avg. Volume6,968,974
30 Day Avg. Volume8,335,558
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)4.18
Price to Sales (P/S)226.59
P/FCF Ratio-8.95
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.69Price Target Upside4.06% Upside
Rating ConsensusHold
Number of Analyst Covering12
EPS Forecast (FY)-0.42
Revenue Forecast (FY)$2.03M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRevenue growth indicates improving commercial or partnership traction from a low base. Sustained expansion would broaden the funding base and provide validation for the company’s development strategy, although scale remains limited.
Strong Gross MarginThe high gross margin suggests that revenue-generating activities can be economically attractive before research and corporate costs. If maintained as revenue scales, it could support operating leverage and improve the path toward eventual profitability.
Low Financial LeverageVery low leverage limits near-term interest and refinancing pressure, preserving financial flexibility while development programs advance. The approximately $264.8M asset base also provides a meaningful capital cushion, subject to ongoing cash burn.
Bears Say
Deep Operating LossesLarge operating and net losses show that the business has not yet converted its development platform into sustainable earnings. Continued losses could require further financing and may delay profitability even if revenue continues to grow.
Persistent Cash BurnMaterial cash outflows relative to revenue make funding capacity a central long-term risk. Unless operating cash use declines or revenue expands substantially, the company may need repeated capital raises to maintain research and development activity.
Clinical-Stage Execution RiskA clinical-stage model depends on successful trial execution, regulatory progress, and eventual product adoption rather than established recurring sales. This creates durable development and commercialization risk while programs remain dependent on research funding.
Atai Beckley N.V. News
ATAI FAQ
What was Atai Beckley N.V.’s price range in the past 12 months?
Atai Beckley N.V. lowest stock price was $3.27 and its highest was $7.45 in the past 12 months.
What is Atai Beckley N.V.’s market cap?
Atai Beckley N.V.’s market cap is $2.72B.
When is Atai Beckley N.V.’s upcoming earnings report date?
Atai Beckley N.V.’s upcoming earnings report date is Nov 12, 2026 which is in 70 days.
How were Atai Beckley N.V.’s earnings last quarter?
Atai Beckley N.V. released its earnings results on Aug 12, 2026. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.107 by $0.017.
Is Atai Beckley N.V. overvalued?
According to Wall Street analysts Atai Beckley N.V.’s price is currently Undervalued.
Does Atai Beckley N.V. pay dividends?
Atai Beckley N.V. pays a Notavailable dividend of $6 which represents an annual dividend yield of N/A. See more information on Atai Beckley N.V. dividends here
What is Atai Beckley N.V.’s EPS estimate?
Atai Beckley N.V.’s EPS estimate is -0.12.
How many shares outstanding does Atai Beckley N.V. have?
Atai Beckley N.V. has 370,864,650 shares outstanding.
What happened to Atai Beckley N.V.’s price movement after its last earnings report?
Atai Beckley N.V. reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.107. Following the earnings report the stock price went up 0.277%.
Which hedge fund is a major shareholder of Atai Beckley N.V.?
Currently, no hedge funds are holding shares in ATAI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atai Beckley N.V. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$7.69 (4.06% Upside)
$7.69 (4.06% Upside)
Blogger Sentiment
Bullish
ATAI Sentiment 85%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 80.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $442.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▼ 11.0%
Last 30 Days ▼ 11.0%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Learn more about TipRanks Smart Score
Company Description
Atai Beckley N.V.
Atai Beckley Inc. operates as a clinical-stage biopharmaceutical firm dedicated to the discovery, advancement, and commercialization of innovative therapeutic solutions for a variety of mental health conditions. The company's operations extend across the United States, Germany, and Canada. Its development pipeline features several key compounds: BPL-003: An intranasally administered formulation of mebufotenin benzoate salt, currently undergoing Phase 2a and 2b clinical trials for its potential in treating both treatment-resistant depression (TRD) and alcohol use disorder. RL-007: An orally active, pro-cognitive neuromodulator, progressing through a Phase 2b study focused on cognitive impairment associated with schizophrenia. ELE-101: A serotonergic psychedelic compound designed to address major depressive disorder. VLS-01: An oral transmucosal film featuring N,N-Dimethyltryptamine, which is in a Phase 2 clinical study for TRD. EMP-01: An orally administered form of R-3,4-methylenedioxy-methamphetamine, also in Phase 2 trials for social anxiety disorder. EGX-A & EGX-B: Non-hallucinogenic 5-HT2A receptor agonists, which are being explored for treatment-resistant depression. Beyond these pipeline assets, the firm also provides COMP360 for psilocybin therapy and GRX-917, aimed at treating anxiety, depression, and various neurological conditions. Originally known as Atai Beckley N.V., the entity officially changed its name to Atai Beckley Inc. in December 2025. Established in 2018, its corporate headquarters are situated in New York, New York.
ATAI Stock 12 Month Forecast
Average Price Target
$7.69
▲(4.06% Upside)
Technical Analysis
Nektar Therapeutics
―
Wave Life Sciences
―
Oric Pharmaceuticals
―
―
Praxis Precision Medicines
―
Ownership Overview
32.13% Insiders
3.53% Mutual Funds
11.46% Other Institutional Investors
42.10% Public Companies and Individual Investors